🇺🇸 FDA
Patent

US 10988778

Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders

granted A61KA61K33/34A61K38/46

Quick answer

US patent 10988778 (Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K33/34, A61K38/46, A61K48/005, A61P